

A Member Board of the American Board of Medical Specialties (ABMS)

# SUBSPECIALTY CERTIFICATION EXAMINATION IN EPILEPSY MEDICINE 2020 Content Blueprint

Nur	Number of questions: 220					
1.	Clinical aspects of epilepsies 8-12%					
2.	Routine EEG	16-20%				
3.	Evaluation	23-27%				
4.	Management	38-42%				
5.	System-based practice issues	1-3%				
6.	Mechanisms of the epilepsies	4-6%				
TO	TOTAL 100%					

**Note:** A more detailed content outline is shown below.



A Member Board of the American Board of Medical Specialties (ABMS)

## SUBSPECIALTY CERTIFICATION EXAMINATION IN EPILEPSY MEDICINE 2020 Content Outline

Cont	ent Are	eas			
01.	Clini	cal asp	ects of	epilepsi	es
	A.	Class	sification	n of seizi	ures
		1.	Gene	ralized	
			a.	Tonic-	clonic (in any combination)
			b.	Absen	ce
				i.	Typical
				ii.	Atypical
				iii.	Absence with special features
					a) Myoclonic absence
					b) Eyelid myoclonia
			C.	Myocl	onic
				i.	Myoclonic
				ii.	Myoclonic atonic
				iii.	Myoclonic tonic
				iv.	Myoclonic-tonic-clonic (clonic-tonic-clonic)
			d.	Clonic	
			e.	Tonic	
			f.	Atonic	
		2.	Focal	onset	
			a.	Withou	ut impairment of consciousness/responsiveness
				i.	With observable motor or autonomic components
					(roughly corresponds to the concept of focal aware with
					motor onset (simple partial) seizure)
				ii.	Nonmotor onset involving subjective sensory or psychic
					phenomena only (corresponds to the concept of focal
					aware with non-motor onset (complex partial) seizure)



b. With impairment of consciousness/ responsiveness (roughly corresponds to the concept of focal impaired awareness (complex partial) seizure)  c. Evolving to a bilateral, convulsive seizure (involving tonic, classical descriptions)	onic,
corresponds to the concept of focal impaired awareness (complex partial) seizure)  c. Evolving to a bilateral, convulsive seizure (involving tonic, cl	onic,
(complex partial) seizure)  c. Evolving to a bilateral, convulsive seizure (involving tonic, cl	
c. Evolving to a bilateral, convulsive seizure (involving tonic, cl	
	у
tonic and clonic, or focal to bilateral tonic-clonic (secondaril	
generalized) components)	
3. May be focal, generalized, or unclear	
a. Epileptic spasms	
b. Atonic	
B. Electro-clinical syndromes and other epilepsies	
1. By age of onset	
a. Neonatal period	
i. Self-limited neonatal seizures (benign familial neona	tal
seizures (BFNS))	
ii. Self-limited familial neonatal epilepsy	
iii. Symptomatic neonatal seizures	
iv. Early myoclonic encephalopathy (EME)	
v. Early infantile epileptic encephalopathy (Ohtahara	
syndrome)	
vi. Other early infantile epileptic encephalopathy (EIEE)	
b. Infancy	
i. Epilepsy of infancy with migrating focal seizures	
(migrating partial seizures of infancy)	
ii. West syndrome	
iii. Myoclonic epilepsy in infancy (MEI)	
iv. Self-limited non-familial infantile epilepsy (benign	
infantile seizures)	
v. Self-limited familial infantile epilepsy (benign familia	l
infantile seizures)	
vi. Severe myoclonic epilepsy of infancy (Dravet syndror	ne)



			vii.	Myoclonic encephalopathy in non-progressive disorders
			Viii.	Hemiconvulsion-hemiplegia-epilepsy syndrome
		C.		hood (1-15 years)
			i.	Febrile seizures plus, genetic epilepsy with febrile seizures
				plus (febrile seizures (FS+) (can start in infancy))
			ii.	Panayiotopoulos syndrome (early onset benign childhood
				occipital epilepsy)
			iii.	Epilepsy with myoclonic-atonic seizures (epilepsy with
				astatic seizures, or Doose syndrome)
			iv.	Childhood (benign) epilepsy with centrotemporal spikes
				(CECTS)
			٧.	Autosomal dominant nocturnal frontal lobe epilepsy
				(ADNFLE)
			vi.	Late-onset childhood occipital epilepsy (Gastaut type)
			vii.	Epilepsy with myoclonic absences (Tassinari syndrome)
			viii.	Lennox-Gastaut syndrome
			ix.	Epileptic encephalopathy with continuous spike-and-
				wave during sleep (CSWS)
			х.	Childhood absence epilepsy (CAE)
			xi.	Acquired epileptic aphasia (Landau-Kleffner syndrome
				(LKS))
		d.	Adole	escence to Adult
			i.	Juvenile absence epilepsy (JAE)
			ii.	Juvenile myoclonic epilepsy (JME)
			iii.	Epilepsy with generalized tonic-clonic seizures alone
			iv.	Autosomal dominant (partial) epilepsy with auditory
				features (ADPEAF)
			٧.	Other familial temporal lobe epilepsies
C.	Less	specific	age rel	ationship
	1.	•		l epilepsy with variable foci (childhood to adult)
	2.		x epilep	1 12
			-1	



	3.	Progressive myoclonus epilepsies (PME)
D.		nctive constellations
	1.	Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with
		HS)
	2.	Rasmussen syndrome
	3.	Focal emotional (gelastic) seizures with hypothalamic hamartoma
E.	Epile	epsies attributed to and organized by structural-metabolic causes
	1.	Structural (including tumors, vascular malformations)
	2.	Infection
	3.	Trauma
	4.	Perinatal insults
	5.	Stroke
	6.	Malformations of cortical development
		a. Neurocutaneous disorders
	7.	Mitochondrial and metabolic disorders
	8.	Autoimmune/paraneoplastic/inflammatory
F.	Epile	epsies of unknown cause
G.	Cond	ditions with epileptic seizures traditionally not diagnosed as a form of
	epile	epsy
	1.	Benign neonatal seizures (BNS)
	2.	Febrile seizures (FS)
H.	Non	epileptic paroxysmal disorders
	1.	Syncope and anoxic seizures
		a. Vasovagal syncope
		b. Reflex anoxic seizures
		c. Breath-holding attacks
		d. Hyperventilation syncope
		e. Compulsive valsalva
		f. Neurological syncope
		g. Imposed upper airways obstructions
		h. Orthostatic intolerance



	i.	Long QT and cardiac syncope
	j.	Hypercyanotic spells
2.	Beha	avioral, psychological, and psychiatric disorders
	a.	Daydreaming/inattention
	b.	Self gratification
	c.	Eidetic imagery
	d.	Tantrums and rage reactions
	e.	Out of body experiences
	f.	Panic attacks
	g.	Dissociative states
	h.	Nonepileptic seizures
	i.	Hallucinations in psychiatric disorders
	j.	Fabricated/factitious illness
3.	Slee	p related conditions
	a.	Sleep related rhythmic movement disorders
	b.	Hypnogogic jerks
	C.	Parasomnias
	d.	REM sleep disorders
	e.	Benign neonatal sleep myoclonus
	f.	Periodic leg movements
	g.	Narcolepsy-cataplexy
4.	Paro	oxysmal movement disorders
	a.	Tics
	b.	Stereotypies
	С.	Paroxysmal kinesigenic dyskinesia
	d.	Paroxysmal nonkinesigenic dyskinesia
	e.	Paroxysmal exercise induced dyskinesia
	f.	Benign paroxysmal tonic upgaze
	g.	Episodic ataxias
	h.	Alternating hemiplegia
	<u>i.</u>	Hyperekplexia
	j.	Opsoclonus-myoclonus syndrome
5.		aine associated disorders
	a.	Migraine with visual aura
	b.	Familial hemiplegic migraine



			c. Benign paroxysmal torticollis
			d. Benign paroxysmal vertigo
			e. Cyclical vomiting
		6.	Miscellaneous events
			a. Benign myoclonus of infancy and shuddering attacks
			b. Jitteriness
			c. Sandifer syndrome
			d. Non-epileptic head drops
			e. Spasmus nutans
			f. Raised intracranial pressure
			g. Paroxysmal extreme pain disorder
	l.	Epide	emiology
	J.	Status	s epilepticus (SE)
		1.	Convulsive
		2.	Myoclonic
		3.	Focal motor
		4.	Tonic status
		5.	Hyperkinetic
		6.	Nonconvulsive with coma
		7.	Nonconvulsive without coma
		8.	Refractory and super-refractory
02.	Rout	tine EEG	i
	A.	Norm	al
		1.	Activation and procedures
		2.	Benign variants
		3.	Artifacts and technical issues
	В.	Interi	ctal epileptiform patterns
	C.		patterns (localization, status, hypsarrhythmia, ictal neonatal seizures)
	D.	Encep	phalopathic patterns
03.	Eval	uation	
	A.	Histo	ry, examination, and semiology
	В.	Chem	ical and metabolic screening
	C.	Speci	alized EEG



		1.	Other supplementary and ambulatory
		2.	Video EEG
		3.	Invasive EEG recordings
			a. Stereo EEG and other depth electrodes
			b. Subdural grid electrodes
			c. Corticography
			i. Functional mapping
	D.	Imag	ing
		1.	Choice of structural imaging (CT, MRI)
			a. Specific protocols
		2.	Functional imaging
			a. SPECT
			b. PET
			c. MEG
			d. MRS
			e. fMRI
			f. Diffusion tensor imaging
	E.	Neur	opsychological testing
	F.	Spina	al fluid analysis (lumbar puncture)
	G.	Gene	tic analysis
04.	Mana	gemer	nt
	A.	Princ	iples of management
		1.	History of new-onset seizure(s)
		2.	Acute seizure management
		3.	Monotherapy vs. polytherapy
		4.	Anti-seizure drug selection
		5.	Dosing and drug monitoring
		6.	Special situations
			a. Neonate
			b. Developmental delay
			c. Cognitively impaired



d.	Elderly
e.	Systemic illness
	i. Hypoxia-ischemia
7. Gender	issues in epilepsy
a.	Fertility and impotence
b.	Catamenial epilepsy
C.	Epilepsy in pregnancy
8. Disco	ntinuation of medication
B. Anti-seizure	therapies
1. Speci	fic drugs (regular and extended-release formulations)
a.	Acetazolamide
b.	ACTH
C.	Carbamazepine
d.	Clonazepam
e.	Clorazepate
f.	Diazepam (oral and rectal gel)
g.	Divalproex sodium
h.	Ethosuximide
i.	Felbamate
j.	Gabapentin
k.	Lacosamide
l.	Lamotrigine
m.	Levetiracetam
n.	Lorazepam
0.	Oxcarbazepine
p.	Phenobarbital
q.	Phenytoin
r.	Pregabalin
S.	Primidone
t.	Rufinamide
u.	Tiagabine



	٧.	Topiramate
	w.	Valproate
	х.	Vigabatrin
	у.	Zonisamide
	Z.	Clobazam
	aa.	Eslicarbazepine
	bb.	Midazolam
	cc.	Perampanel
	dd.	Cannabidiol
	ee.	Brivaracetam
	ff.	Stiripentol
	gg.	Cenobamate
	hh.	Other
2.	Mecha	anisms of action of above drugs
3.	Drug i	nteractions (pharmacokinetic/pharmacodynamic)
4.	Drug t	oxicities and teratogenicity
5.	Monit	oring principles
6.	Other	therapies
	a.	Diet therapies
		i. Indications
		ii. Patient selection
		iii. Monitoring
		iv. Duration
	b.	Hormonal therapies
		i. ACTH
		ii. Other steroidal therapies
	c.	Immunoglobulin therapy
	d.	Vagus nerve stimulation
	e.	Other forms of stimulation
	f.	Alternative and complementary therapies
C. Surgio	cal ther	apies



	1.	Indications for referral
	•	a. Definition of intractable epilepsies
		b. Duration of epilepsy and failure of response to medication
	2.	Evaluation for possible surgery
		a. Wada testing and special neuropsychological evaluation
	3.	Types of surgical procedure
		a. Focal resections
		i. Temporal lobe
		ii. Frontal lobe
		iii. Parieto-occipital
		b. Hemispherectomies
		i. Neocortical
		ii. Standard anterior temporal lobectomy
		iii. Selective mesial resections
		c. Multiple subpial transections
		d. Corpus callosotomies
		e. Repeat surgical procedures
		f. Other
	4.	Complications of surgery
		a. Outcome
D.	Stati	us epilepticus
	1.	Acute management
	2.	Drug therapy
		a. First-line
		b. Second-line
		c. Third-line
	3.	Anesthetic therapies
	4.	Continuous EEG monitoring
	5.	Systemic complications
	6.	Outcome
E.	Psyc	hosocial management



		1.	Patient and family education
			a. Drug information
			b. Compliance
			c. Safety issues
			i. Sleep deprivation
			ii. Sports participation
			iii. Drug and alcohol risks
			iv. Driving regulations
			v. Piloting regulations
			vi Bathing
		2.	School and work situations
			a. IEPs
			b. ADA
			c. Disability
		3.	Quality of life
			a. Dating
			b. Marriage
			c. Stigma
		4.	Sleep and epilepsy
		5.	Prognosis and counseling
	F.	Como	prbidities
		1.	Psychiatric issues
		2.	Cognitive issues
		3.	Mortality (SUDEP)
		4.	Migraine
		5.	Medical complications
0.5	Cycl	6.	Sleep
05.			is policy issues (education, driving, research funding)
	Α.		ic policy issues (education, driving, research funding)
-	В.		king with educational systems
	C.	⊾mp	loyment issues



	D.	Clinical trials of new therapies
	E.	Forensic epilepsy
	F.	Ethics
06.	Mechanisms of the epilepsies	
	A.	Pathophysiology of the epilepsies
	B.	Physiological basis of epileptic EEG patterns
	C.	Pathology of the epilepsies
TOTAL		